Flexstep Technology News Today

A collaborative group of Cedars-Sinai investigators suggest artificial intelligence can accurately assess volume, density of heart fat-both of which are linked to cardiovascular risk

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the closing of its $4.9M preferred Series A1...

Grant Proceeds Will Support Pre-Clinical Studies

/PRNewswire/ -- Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced today that it has been awarded a Phase II Small...

First-In-Human Use Reported for Bioresorbable Efemoral Vascular Scaffold System New bioresorbable stent aims to improve outcomes for patients with peripheral arterial disease A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right. December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular scaffold system (EVSS) with FlexStep Technology in th...

Share this article Share this article LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the first-in-human (FIH) use of the companys Efemoral ™ Vascular Scaffold System (EVSS) with FlexStep ™ Technology in the EFEMORAL I FIH clinical study. Designed to address a broad range of patients, this innovative technology offers a new approach to treat peripheral arterial disease (PAD), alleviate symptoms...